Scientists Race to Create Vaccine for New Ebola Strain

Scientists around the world just launched an urgent mission to develop vaccines and treatments for a dangerous Ebola strain that currently has no cure.

The Bundibugyo strain is spreading through the Democratic Republic of Congo and Uganda, affecting areas already challenged by conflict. This week, three research teams received $60 million to fast-track their vaccine development, marking a major step forward in the global response.

Oxford University is leading the charge with a vaccine that could enter trials within two to three months. The jab uses the same proven technology as their COVID-19 vaccine, and India's Serum Institute has committed to producing as many doses as needed.

The International Aids Vaccine Initiative is developing another promising candidate using technology from an existing Ebola vaccine that works against a different strain. Their vaccine is expected to reach clinical trials within seven to nine months.

Moderna is also joining the effort with an mRNA vaccine, the same technology that helped end the COVID pandemic. The company plans to move "with urgency and scientific rigor" to support communities facing the outbreak.

Beyond vaccines, researchers are breaking new ground with treatment options. Three existing medicines show promise as potential Bundibugyo treatments, including remdesivir, the antiviral drug used during COVID.

The Ripple Effect

The real game-changer is a prevention pill called obdeldesivir that could stop Ebola before it develops. Doctors will give the drug to people who've been in contact with infected patients, testing whether daily pills for 10 days can prevent illness. In monkey studies, it provided up to 100% protection against other Ebola strains when given within 24 hours of exposure.

This marks the first time researchers have tested a prevention drug during an Ebola outbreak. If successful, it could transform how the world responds to future outbreaks by protecting healthcare workers and family members before they get sick.

Professor Teresa Lambe from Oxford's Pandemic Sciences Institute emphasized the speed of the response. Teams are conducting animal studies simultaneously across multiple countries to accelerate the timeline.

Dr. Richard Hatchett from the Coalition for Epidemic Preparedness Innovations captured the urgency perfectly: "Every day counts in the race against this deadly disease."

While security challenges have complicated trial setup in affected regions, researchers are ready to begin the moment conditions allow. Multiple teams are now seeking regulatory approval to start treating patients and testing their innovations.

The coordinated global response shows how lessons from COVID and previous Ebola outbreaks are helping scientists move faster than ever before to protect vulnerable communities.